Generation of two human isogenic iPSC lines from fetal dermal fibroblasts.
Clicks: 222
ID: 14767
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
73.8
/100
222 views
178 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #22 of 38 articles by views in Stem cell research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Two isogenic hiPSC lines, ZIPi013-B and ZIPi013-E, were generated by reprogramming fetal dermal fibroblasts with episomal vectors. Previously, the same fetal fibroblasts were reprogrammed multiple times in a study comparing other reprogramming methods. As a consequence, the genomes have been sequenced multiple times. Both new cell lines offer the opportunity to study basic stem cell biology and model human disease. They can be applied as reference cell lines for creating isogenic clones bearing disease mutations on a well-characterized genomic background, as both cell lines have demonstrated excellent differentiation capacity in multiple labs. Resource table.
| Reference Key |
tandon2018generationstem
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Tandon, Rashmi;Brändl, Björn;Baryshnikova, Natalya;Landshammer, Alexandro;Steenpaß, Laura;Keminer, Oliver;Pless, Ole;Müller, Franz-Josef; |
| Journal | Stem cell research |
| Year | 2018 |
| DOI |
S1873-5061(18)30247-2
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.